Ori Biotech Ltd., a leader in cell and gene therapy (CGT) manufacturing technology, has shared details of its strategic expansion plan following its $100 million Series B funding round in January 2022, including adding key expertise and personnel and new facilities globally in order to rapidly transition into the launch of its innovative cell and gene therapy (CGT) manufacturing platform.   “Our recent Series B funding has enabled us to continue to invest in rapid expansion in preparation for ...